BioBAY: Powering Global Biotech Innovation from Suzhou
During media interviews, many entrepreneurs based in BioBAY spoke highly of the park.
Chen Li, founder of Ginkgo Tree Pharmaceutical, stated, “We were deeply impressed by the professionalism of BioBAY’s entire service team. Beyond specific early-stage support measures, BioBAY’s public platforms have provided a conducive R&D and growth environment for start-ups in the park.”
Luo Peizhi, President of Adagene Inc., commented: “Suzhou’s elegant and tranquil natural and cultural environment offers a sense of comfort, while the scientific, educational, and industrial ecosystem of Suzhou BioBAY provides entrepreneurs with a rich atmosphere for innovation. Every year, Cold Spring Harbor Asia hosts numerous academic exchange events that bring together top scientists from around the world. As companies based here, we can attend these events free of charge, engage in face-to-face exchanges and discussions with researchers on the latest medical advances, and create excellent opportunities for collaboration.”
In 2019, BioBAY turned twelve. It likes to refer to itself as “Bio Village” and its tenant companies as “honored guests.” By providing high-quality corporate services, it makes entrepreneurs feel at home; by integrating the industrial chain within the park, it alleviates their concerns. Pang Junyong, President of BioBAY, stated in an interview: “Since its inception, BioBAY has always regarded itself as an integral part of the industry—this is our distinctive DNA. Our core mission is to build an ecosystem that delivers added value to drive industrial development, creating value through services.”
After more than a decade of cultivation in the biopharmaceutical sector, BioBAY has finally entered its harvest season. Innovent Biologics and CStone Pharmaceuticals have successively listed on the Hong Kong Stock Exchange; Innovent’s PD-1 monoclonal antibody, Tyvyt (sintilimab), was successfully launched in 2019, becoming the second domestically produced PD-1 monoclonal antibody to reach the market. According to the “Top 50 National High-Tech Zones for Comprehensive Competitiveness in the Biopharmaceutical Industry (2016)” released by the China National Center for Biotechnology Development, BioBAY ranked first among the top ten parks in terms of biopharmaceutical industry competitiveness. It also ranked among the leaders across all sub-categories published in the report. Pang Junyong noted, “Many industry professionals have told me that projects of comparable quality from BioBAY are generally valued 30% higher than those from other regions.” This is the strongest testament to BioBAY’s recognition within the industry.
BioBAY was formerly known as Suzhou Bio-Nano Park. On June 27, 2007, the opening ceremony of Suzhou Bio-Nano Park was held, marking its official launch. This date is recognized as BioBAY’s “birthday.” On June 8, 2017, in celebration of BioBAY’s 10th anniversary, Suzhou Bio-Nano Park was officially renamed Suzhou Biomedical Industrial Park.
Just 100 kilometers from BioBAY lies the Shanghai Zhangjiang Hi-Tech Park. When BioBAY was first established, Zhangjiang had already been developing for over a decade, hosting numerous top-tier domestic and international pharmaceutical companies. For the newly launched BioBAY, engaging in direct competition with Shanghai Zhangjiang would have been akin to striking a stone with an egg. Therefore, from the outset, BioBAY adopted a strategy of differentiated competition, targeting startups and early-stage companies in the biotech high-tech sector, while focusing its industry scope on three major areas: drug development, medical devices, and biotechnology. This positioning remains the cornerstone of BioBAY’s development to this day.
In its early stages, BioBAY leveraged Suzhou’s “Talent Recruitment and Intelligence Introduction” initiative to attract numerous domestic and international universities and research institutes to the surrounding area, including premier institutions such as the Suzhou Institute for Drug Innovation of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and the Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences. Meanwhile, BioBAY engaged with Chinese professional associations to attract talent and retained them through preferential policies, including financial incentives and talent subsidies. This concentration of talent enhanced BioBAY’s appeal to startups, resulting in the aggregation of more than 400 companies within the park in just a few years.
BioBAY is currently undergoing continuous expansion. In addition to the initial phase of the Suzhou BioBay Industrial Park, BioBAY has developed Phase II of the park and collaborated with Changshu to establish the Su-Yu Biopharmaceutical Industrial Park. Through this model of collaborative industrial parks, BioBAY aims to leverage its years of accumulated expertise in park operations, promote regional integrated cooperation, and provide support to more startups in need of incubation resources.
Continuously attending to the needs of entrepreneurs and addressing their diverse and complex requirements through tailored approaches reflects the humanistic care that BioBAY extends to dedicated founders. For entrepreneurs in the capital-intensive biopharmaceutical sector, funding needs are particularly urgent; thus, BioBAY established BioCAPITAL within the park to bring together outstanding domestic and international venture capital firms and build a bridge for investment and financing. To help returning overseas entrepreneurs address their children’s education needs, the park specially founded a school for the children of overseas-returnee talents. Recognizing entrepreneurs’ need for communication with service departments, BioBAY set up a one-stop customer service center to provide zero-distance services to startups, including company registration and environmental compliance consulting.
As the needs of entrepreneurs continue to evolve, BioBAY has been continuously adjusting its service offerings and delivery methods accordingly. The service team’s mindset and capabilities have grown through the process of tackling new tasks, establishing BioBAY as a leading biopharmaceutical “incubator + accelerator” in China.
Meanwhile, BioBAY is also an industrial park established with government support. For a long time, it has served as an incubator and acted as a bridge of communication between enterprises and the government. The Suzhou Industrial Park’s open-mindedness, strong reform orientation, and flexible policies make it easier to tailor support to the development of local high-tech enterprises. The market-driven innovative mindset that Suzhou has explored over the years has further solidified BioBAY’s foundation for innovation.
In addition, BioBAY has also ventured into the venture capital sector. In October 2013, BioBAY and New Yuan Holdings Group jointly launched the New Yuan Bio-Fund. Based in BioBAY, this fund focuses on driving rapid growth in the production capacity and scale of the biopharmaceutical industry. BioBAY has also participated as a limited partner in well-known industry funds such as Tonghe Yucheng, Medtronic Fund, Taifu Capital, and Lilly Asia Ventures. These initiatives have strengthened BioBAY’s ties with the capital market, enabling it to more effectively assist companies within the park in securing financial support.
Attracting the Cold Spring Harbor Laboratory Asia Conference Center to settle in BioBAY marked a significant milestone in its history. Cold Spring Harbor Laboratory is a renowned molecular biology research center in the United States, having produced seven Nobel laureates. Prior to establishing its presence in BioBAY, Dr. James Watson, then head of Cold Spring Harbor Laboratory, personally led a delegation to Suzhou for an inspection, where he witnessed firsthand the local government’s determination and concrete actions to build China’s most internationalized industrial park. Consequently, in 2009, Cold Spring Harbor Laboratory established its only overseas branch—Cold Spring Harbor Asia—in Suzhou.
Cold Spring Harbor Asia aims to build a premier academic conference platform, primarily serving the Asia-Pacific region and focusing on advancing the life sciences industry in China and across Asia-Pacific. Its dozens of annual academic conferences greatly benefit local professors, students, and entrepreneurs. Attendees traveling from afar also have the opportunity to engage with companies located within the BioBAY park outside of conference sessions, providing numerous opportunities for exchange and collaboration for startups in the park.
BioBAY has consistently focused on the upstream and downstream ecosystem of companies within its park, deliberately integrating these supply chains to foster connectivity. This strategic approach has become one of BioBAY’s core attractions. As early as 2011, BioBAY consolidated the public technical service platforms within its park and established a wholly-owned subsidiary named “BioTOP.” Initially, BioTOP served merely as a small-scale platform offering instrument rental services to enterprises. After years of development, BioTOP has evolved into an independent third-party analytical testing and technical service company accredited by CNAS (China National Accreditation Service for Conformity Assessment). It provides a comprehensive range of upstream services to biopharmaceutical companies in the park, including analytical testing, biological technical services, procurement of reagents and consumables, personnel technical training, and international logistics support for biological materials.
In May 2013, BioBAY partnered with QIAGEN from Germany. The two parties established a joint venture, the QIAGEN (Suzhou) Translational Medicine Center, which was the first R&D enterprise in China centered on translational medicine. QIAGEN is a multinational corporation dedicated to solutions for biomolecular sample preparation and is one of the key upstream pillars in the biopharmaceutical industry. By attracting QIAGEN to set up operations in Suzhou, BioBAY has enabled biopharmaceutical companies within the park to conveniently access world-class laboratory service platforms and technologies.
In March 2018, Suzhou Bridge Biologics, invested by BioBAY, officially commenced operations within BioBAY. As a comprehensive contract development and manufacturing organization (CDMO) specializing in biologics, Suzhou Bridge Biologics provides biopharmaceutical companies with one-stop solutions ranging from DNA sequence to commercial-scale production for preclinical and clinical Phase I, II, and III biologic products. The company chose Suzhou due to its favorable overall environment and robust industrial support infrastructure. The addition of Suzhou Bridge Biologics has filled the gap in R&D and manufacturing services at BioBAY, thereby fully integrating the biopharmaceutical R&D industry chain within the park.
From BioTOP to Qiagen and then to Suzhou Biologics, BioBAY has leveraged multiple channels—including self-development, introduction, and investment—to integrate the entire biopharmaceutical industry chain within the park, thereby eliminating concerns for biopharmaceutical enterprises located there.
Innovent Biologics, Alphamab Oncology, CStone Pharmaceuticals, and a host of other biopharmaceutical companies based in BioBAY have now become household names. Innovent Biologics and CStone Pharmaceuticals have even gone public on the Hong Kong Stock Exchange. Yet when they first entered BioBAY, they were all startups with uncertain futures. This is precisely what underscores BioBAY’s foresight. It set its sights on these early-stage biopharmaceutical ventures before the industry had truly taken off. Now that the biopharmaceutical sector has entered a harvest phase, BioBAY has likewise reaped the rewards in terms of reputation and industry standing.
In January 2012, Innovent Biologics moved into BioBAY. At that time, Innovent had been established for only five months, with a team of fewer than 20 members. Although it had secured $5 million in Series A financing led by Fidelity, this amount was still tight compared to the R&D expenses required in biopharmaceutical development. BioBAY attracted Innovent’s entry with its high-quality corporate services and comprehensive supporting facilities. Innovent often joked that one-third of their first drug pipeline—IBI-301, their “golden egg”—was hatched using someone else’s hen. The public laboratory platform at BioBAY was a key component of this “someone else’s hen.”
Since joining BioBAY, Innovent Biologics has enjoyed smooth and rapid growth. Just five months after settling in BioBAY, the company secured a $30 million Series B financing round led by Lilly Asia Ventures, with Fidelity Investments participating as a co-investor. Its landmark out-licensing deal with Eli Lilly, valued at up to $3.3 billion for overseas markets, is frequently cited as a classic example of Chinese innovative medicines going global. Coupled with its listing on the Hong Kong Stock Exchange and the commercial launch of Tyvyt (sintilimab), Innovent Biologics has become a benchmark enterprise in China’s innovative drug sector. BioBAY served as the starting point for Innovent’s journey, providing the initial platform and support that fueled its development over the years.
For BioBAY, as China’s biopharmaceutical industry transitions from its nascent stage to maturity, it is time to recalibrate its strategy. Companies within the park are not only increasing in number but also growing in scale. For promising projects, BioBAY needs to demonstrate greater boldness in investment and actively promote key initiatives deserving of targeted support. Meanwhile, BioBAY continues to influence government policy through its projects, leveraging its flexibility to ensure that policies align with the localized development needs of enterprises.
Corporate services will remain a core pillar of BioBAY’s development and the cornerstone of its foundation. At its inception, BioBAY established the “3P” philosophy—Professional, Pragmatic, and Passionate—for its service team, aiming to build a high-quality service-oriented team. Now, BioBAY has introduced the “3C” philosophy—Concentration, Collaboration, and Creativity—with the goal of transforming from a service-oriented team into a service-oriented community, thereby providing enterprises with more in-depth service offerings.
In terms of corporate layout, BioBAY will strategically introduce diverse enterprises with an international perspective, emphasizing balanced development across different sectors. On a broad scale, the park will cover multiple fields such as innovative drugs, high-end medical devices, cell therapy, and gene technology. On a more focused scale, it will target specific disease areas including oncology, cardiovascular diseases, and metabolic disorders. Through this approach, BioBAY aims to ensure differentiated development among its tenant companies, avoid homogenization and internal competition, and facilitate communication and collaboration within the park.
Xu Ting, President of Alphamab Oncology, stated in an interview, “When Alphamab Oncology first settled in BioBAY in 2009, there were only a dozen companies actually operating within the park. The changes BioBAY has undergone over the years are a microcosm of the development of China’s entire biotechnology industry.”
Indeed, if China’s biopharmaceutical industry has taken root and sprouted over the past decade or more, BioBAY has served as the fertile soil beneath the feet of rapidly growing biopharmaceutical companies. Located in the Yangtze River Delta region, BioBAY has risen to become a leading biopharmaceutical park in China within just over ten years, leveraging its high-quality services and a differentiated competitive development model. In the future, “BioVillage” will continue to provide dedicated service to its “guests,” enabling the biopharmaceutical industry to grow into towering trees on the land of Suzhou.
